On this page
Econazole Nitrate
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Econazole Nitrate | 10 mg/g | 1442585 | — |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Azole Antifungal [EPC] | EPC | All 44 members |
| Azoles [CS] | CS | All 44 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 076479-001 | ECONAZOLE NITRATE | CREAM | ECONAZOLE NITRATE | Prescription | AB | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | June 23, 2004 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260622). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Econazole nitrate cream is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum , in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Sufficient econazole nitrate cream, 1%, should be applied to cover affected areas once daily in patients with tinea pedis, tinea cruris, tinea corporis, and tinea versicolor, and twice daily (morning and evening) in patients with cutaneous candidiasis. Early relief of symptoms is experienced by the majority of patients and clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks and tinea pedis for one month in order to reduce the possibility of recurrence. If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Econazole Nitrate Cream is contraindicated in individuals who have shown hypersensitivity to any of its ingredients.
Warnings
openFDA Drug LabelingWARNINGS Econazole Nitrate Cream is not for ophthalmic use.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS During clinical trials, approximately 3% of patients treated with econazole nitrate cream, 1 % reported side effects thought possibly to be due to the drug, consisting mainly of burning, itching, stinging, and erythema. One case of pruritic rash has also been reported.
Drug Interactions
openFDA Drug LabelingDrug Interactions Warfarin Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulation effect. Most cases reported product application with use under occlusion, genital application, or application to large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.
Description
openFDA Drug LabelingDESCRIPTION Econazole nitrate cream contains the antifungal agent, econazole nitrate USP 1%, in a water-miscible base consisting of benzoic acid, butylated hydroxytoluene, mineral oil, oleoyl polyoxylglycerides PEG-6-32 stearate/glycol stearate and purified water. The white to off-white soft cream is for topical use only. Chemically, econazole nitrate is 1-[2-{(4-chloro-phenyl) methoxy}-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole mononitrate. Its structure is as follows: Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Overdosage of econazole nitrate in humans has not been reported to date. In mice, rats, guinea pigs and dogs, the oral LD 50 values were found to be 462, 668, 272, and >160 mg/kg, respectively.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Econazole Nitrate Cream, 1% contains econazole nitrate USP. The white to off-white homogenous cream is available as follows: 15 g aluminum tube NDC 59651-945-14 30 g aluminum tube NDC 59651-945-30 85 g aluminum tube NDC 59651-945-85 Store econazole nitrate cream below 30°C (86°F). To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch for voluntary reporting of adverse reactions. Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 032, India Revised: 04/2026
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: ECONAZOLE NITRATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 59651-945-14 | 59651-945 | Aurobindo Pharma Limited | 1 TUBE in 1 CARTON (59651-945-14) / 15 g in 1 TUBE | March 13, 2026 |
| 59651-945-30 | 59651-945 | Aurobindo Pharma Limited | 1 TUBE in 1 CARTON (59651-945-30) / 30 g in 1 TUBE | March 13, 2026 |
| 59651-945-85 | 59651-945 | Aurobindo Pharma Limited | 1 TUBE in 1 CARTON (59651-945-85) / 85 g in 1 TUBE | March 13, 2026 |
| 63629-8645-1 | 63629-8645 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8645-1) / 15 g in 1 TUBE | December 21, 2006 |
| 63629-8646-1 | 63629-8646 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8646-1) / 30 g in 1 TUBE | November 10, 2006 |
| 63629-8647-1 | 63629-8647 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8647-1) / 85 g in 1 TUBE | August 8, 2006 |
| 72162-1410-2 | 72162-1410 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1410-2) / 85 g in 1 TUBE | August 17, 2023 |
| 72162-1410-3 | 72162-1410 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1410-3) / 30 g in 1 TUBE | August 17, 2023 |
| 72162-1410-4 | 72162-1410 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1410-4) / 15 g in 1 TUBE | August 17, 2023 |
| 21922-111-04 | 21922-111 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-111-04) / 15 g in 1 TUBE | July 1, 2026 |
| 21922-111-05 | 21922-111 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-111-05) / 30 g in 1 TUBE | July 1, 2026 |
| 21922-111-15 | 21922-111 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-111-15) / 85 g in 1 TUBE | July 1, 2026 |
| 45802-466-11 | 45802-466 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-466-11) / 30 g in 1 TUBE | November 10, 2006 |
| 45802-466-35 | 45802-466 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-466-35) / 15 g in 1 TUBE | December 21, 2006 |
| 45802-466-53 | 45802-466 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-466-53) / 85 g in 1 TUBE | August 8, 2006 |
| 68788-8170-3 | 68788-8170 | Preferred Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (68788-8170-3) / 30 g in 1 TUBE | April 11, 2022 |
| 68788-8174-1 | 68788-8174 | Preferred Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (68788-8174-1) / 15 g in 1 TUBE | April 27, 2022 |
| 68788-8884-3 | 68788-8884 | Preferred Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (68788-8884-3) / 30 g in 1 TUBE | June 2, 2025 |
| 51672-1303-1 | 51672-1303 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1303-1) / 15 g in 1 TUBE | November 26, 2002 |
| 51672-1303-2 | 51672-1303 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1303-2) / 30 g in 1 TUBE | November 26, 2002 |
| 51672-1303-8 | 51672-1303 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1303-8) / 85 g in 1 TUBE | November 26, 2002 |
| 59651-945 | 59651-945 | Aurobindo Pharma Limited | — | March 13, 2026 |
| 63629-8645 | 63629-8645 | Bryant Ranch Prepack | — | August 8, 2006 |
| 63629-8646 | 63629-8646 | Bryant Ranch Prepack | — | August 8, 2006 |
| 63629-8647 | 63629-8647 | Bryant Ranch Prepack | — | August 8, 2006 |
| 72162-1410 | 72162-1410 | Bryant Ranch Prepack | — | August 8, 2006 |
| 21922-111 | 21922-111 | Encube Ethicals, Inc. | — | July 1, 2026 |
| 45802-466 | 45802-466 | Padagis Israel Pharmaceuticals Ltd | — | August 8, 2006 |
| 68788-8170 | 68788-8170 | Preferred Pharmaceuticals Inc. | — | April 11, 2022 |
| 68788-8174 | 68788-8174 | Preferred Pharmaceuticals Inc. | — | April 27, 2022 |
| 68788-8884 | 68788-8884 | Preferred Pharmaceuticals Inc. | — | August 8, 2006 |
| 51672-1303 | 51672-1303 | Sun Pharmaceutical Industries, Inc. | — | November 26, 2002 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.